Next Article in Journal
Myeloid Cell Leukemia 1 Small Molecule Inhibitor S63845 Synergizes with Cisplatin in Triple-Negative Breast Cancer
Next Article in Special Issue
First-Line Chemoimmunotherapy versus Sequential Platinum-Based Chemotherapy Followed by Immunotherapy in Patients with Non-Small Cell Lung Cancer with ≤49% Programmed Death-Ligand 1 Expression: A Real-World Multicenter Retrospective Study
Previous Article in Journal
Tumor Infiltrating Lymphocytes (TILS) and PD-L1 Expression in Breast Cancer: A Review of Current Evidence and Prognostic Implications from Pathologist’s Perspective
Previous Article in Special Issue
Immunotherapy through the Lens of Non-Small Cell Lung Cancer
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 15
Issue 18
10.3390/cancers15184480
Review Report
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Article
Peer-Review Record

Gene Expressions and High Lymphocyte Count May Predict Durable Clinical Benefits in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Immune Checkpoint Inhibitors

Cancers 2023, 15(18), 4480; https://doi.org/10.3390/cancers15184480
by Mette T. Mouritzen 1,2,3,*, Morten Ladekarl 1,2,3, Henrik Hager 4,5,†, Trine B. Mattesen 4, Julie B. Lippert 4, Malene S. Frank 6,7, Anne K. Nøhr 2,8, Ida B. Egendal 2,8 and Andreas Carus 1,2,3
Reviewer 1: Anonymous
Reviewer 2:
Jian-Guo Zhou
Reviewer 3:
Luca Giacomelli
Cancers 2023, 15(18), 4480; https://doi.org/10.3390/cancers15184480
Submission received: 20 June 2023 / Revised: 16 August 2023 / Accepted: 31 August 2023 / Published: 8 September 2023
(This article belongs to the Special Issue Immunotherapy with Checkpoint Inhibitors for Non-small Cell Lung Cancer)

Round 1

Reviewer 1 Report

* The authors investigated the factors affecting the prognosis of using immune checkpoint inhibitors in patients with non-small cell lung cancer.

* The title must not contain any abbreviation.

* Line 37: Please define NSCLC in its first mention.

* The introduction is well written.

* Line 144: Please, add more details about immunohistochemistry and put the representative figures in the supplementary files.

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Reviewer 2 Report

This work is very interesting and meaningful for IO. However,  I have some issues needs to point out.

1. This title is too wide, I suggest the authors only focus on 1-2 part, or change to the clinical, pathological, and gentic related ICI benefit.

2. I suggest the authors add funtional analysis to explain why those signature could predict IO benefit.

3. I also suggest the authors comparison those finding biomarkers with published biomarkers. eg. IMpower150, IMvigor210, IMmotion150 etc.

The authors are native English speakers, so I don't have any other comments about the quality of English language.

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Reviewer 3 Report

This is a very good study investigating the predictive potential of gene expression profiling peripheral immune cell counts, and clinical characteristics in patients with NSCLC treated with immunotherapy.

The paper is well written and data are well presented. I particularly liked the choice of DCB as primary endpoint.

Actually, I do not have any specific comment. The main limitation of the study, i.e. the very limited number of patients with available GEP, is acknowledged, but maybe the Authors can do some more effort to discuss it.

 

English is fine

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Back to TopTop